ticagrelor / Generic mfg. - LARVOL DELTA

Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population. (PubMed, Drug Des Devel Ther) - "For Chinese elderly, PBPK models for four drugs (ticagrelor, rivaroxaban, alprazolam, midazolam) showed strong agreement with observed data. In conclusion, PBPK models for 50 commonly prescribed drugs within the Chinese elderly population were developed, tackling general data gaps associated with these specific medications. Medication plans were developed specifically tailored for the elderly population, presenting an alternative methodology and perspective for the implementation of individualized and rational medication practices."

Journal • PK/PD data • Psychiatry

Foundational Insights and Costs of Care Associated With Perioperative Ticagrelor Management for Patients Undergoing Coronary Artery Bypass Graft Surgery: A Medical Chart Audit Review (ISPOR 2025) - "Perioperative ticagrelor management for patients undergoing CABG is expensive, with high HCRU and corresponding costs, particularly prior to surgery. This study highlights the need for a rapid ticagrelor reversal agent to reduce the clinical and economic burden of antiplatelet washout among patients undergoing CABG surgery."

Clinical • Cost of care • Review • Surgery • Cardiovascular • Infectious Disease

Medical Record Review to Characterize the Foundational Insights and Costs Associated with Intracerebral Hemorrhage (ICH) Management Among Ticagrelor-Treated Patients (ISPOR 2025) - "Ticagrelor-treated patients hospitalized for ICH management require substantial HCRU due to frequent complications, prolonged hospital stays, and costly pharmacy and/or blood product use with uncertain clinical benefits. This study highlights the unmet need for more targeted treatment strategies to reduce the clinical and economic burden associated with ICH management related to ticagrelor use."

Clinical • Review • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders • Mood Disorders

Healthcare Resource Utilization Among Ticagrelor-Treated Patients With Bleeding or Undergoing Urgent Surgery in the United States: A Real-World, Retrospective Claims Analysis (ISPOR 2025) - "HCRU associated with bleeding or surgical intervention among ticagrelor-treated patients was similarly substantial among payer types. A specific ticagrelor antidote that rapidly restores platelet function during bleeding, while balancing perioperative thrombosis risk, may offer a potential solution for this complex, costly ACS population."

HEOR • Real-world • Real-world evidence • Retrospective data • Surgery • Acute Coronary Syndrome • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Hematological Disorders • Thrombosis

Unseen Hazards: Rhabdomyolysis in CKD Patients Due to Ticagrelor and Colchicine (ERA 2025) - No abstract available

Clinical • Chronic Kidney Disease

Diagnostic Challenges in Atypical Presentations of Spontaneous Vertebral Artery Dissection. (PubMed, Cureus) - "Dual antiplatelet therapy was initiated with aspirin and Brilinta. This case highlights the importance of recognizing and diagnosing VAD in a timely manner, especially in patients with atypical symptoms."

Journal • Cardiovascular • Ischemic stroke • Ophthalmology • Otorhinolaryngology • Pain • Vertigo

DEDAPT-TICA: Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke (clinicaltrials.gov) - P2/3 | N=100 | Recruiting | Sponsor: Mazandaran University of Medical Sciences | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Apr 2024

Enrollment open • Trial initiation date • Cardiovascular • Ischemic stroke

Ticagrelor monotherapy for acute coronary syndromes. (PubMed, Lancet) - No abstract available

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular

Ticagrelor monotherapy for acute coronary syndromes - Authors' reply. (PubMed, Lancet) - No abstract available

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular

Ticagrelor monotherapy for acute coronary syndromes. (PubMed, Lancet) - No abstract available

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular

A Novel Approach to Gastrointestinal Bleeding Risk Stratification and Proton Pump Inhibitor Effectiveness in Patients with Acute Coronary Syndrome on Dual Antiplatelet Therapy: A Nationwide Retrospective Cohort Study. (PubMed, Cardiovasc Drugs Ther) - "The mARC-HBR criteria enhance the identification of high GI bleeding risk patients with ACS and may inform targeted PPI use, given the observed associations suggesting potential benefit in high-risk ticagrelor users and limited effect in low-risk groups."

Journal • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Gastroenterology • Gastrointestinal Disorder

Ticagrelor monotherapy for acute coronary syndromes. (PubMed, Lancet) - No abstract available

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular

Rare Case Report of Ticagrelor-Induced Hepatotoxicity. (PubMed, Korean J Gastroenterol) - "Ticagrelor, a potent P2Y12 receptor inhibitor, is used widely to manage acute coronary syndrome owing to its superior efficacy in reducing cardiovascular events compared to clopidogrel. Ticagrelor was discontinued, and the subsequent liver enzyme levels gradually returned to normal. This case highlights the need for careful monitoring of the liver function in patients receiving ticagrelor."

Journal • Acute Coronary Syndrome • Autoimmune Hepatitis • Cardiovascular • Hepatology • Immunology • Liver Failure • Oncology

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience. (PubMed, BMC Cardiovasc Disord) - P=N/A | "Eptifibatide rapidly reduced the PAR in patients with unstable angina pectoris and reduced the rates of MI, in-hospital MACEs, and 12-month MI, without increasing bleeding events. The combined use of eptifibatide and ticagrelor was safe and effective."

Biomarker • Journal • Retrospective data • Cardiovascular • Myocardial Infarction • CRP • NPPB

Clopidogrel vs. ticagrelor in ST-elevation myocardial infarction complicated by cardiogenic shock undergoing primary PCI : Findings from a National, multicenter registry. (PubMed, Thromb J) - P=N/A | "Our findings suggest that the choice of either ticagrelor or clopidogrel was feasible as a P2Y12 inhibitor for dual anti-platelet strategy in STEMI-CS patients undergoing pPCI, as no significant difference between these two agents was observed in all-cause mortality and major bleeding during hospitalization."

Journal • Cardiovascular • Myocardial Infarction

Discovery of hypoglycemic and cardiovascular drugs as the effective inhibitors on human pancreatic lipase. (PubMed, Chem Biodivers) - "Among them, ticagrelor (HC-14), prasugrel (HC-18), amlodipine (HC-26), simvastatin (HC-32), and lovastatin (HC-33) had strong inhibitory activity against hPL...Further studies showed that HC-14 significantly inhibited hPL activity in AR42J cells, resulting in dose-dependent inhibition. Overall, the above results suggest that ticagrelor is a cardiovascular drug that inhibits hPL, which also provides an important reference for the search and development of other drugs for the treatment of obesity."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity

Risk of Complications Following Medialization Thyroplasty in Patients on Anticoagulation (COSM 2025) - "Patients taking AC/AP (aspirin, warfarin, apixaban, edoxaban, rivaroxaban, dabigatran, dipyridamole, ticagrelor, prasugrel, clopidogrel, cilostazol, dalteparin, enoxaparin) within 1 month of the procedure were identified and compared to those not taking these medications. Based on analysis of a large healthcare database, MT performed on AC/AP is associated with higher rates of post-operative dysphagia and airway compromise but not postoperative hemorrhage/hematoma."

Clinical • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease

Perioperative Antithrombotic Strategies in Vascular Surgery: A Survey in Germany. (PubMed, Health Sci Rep) - "Acetylsalicylic acid was discontinued before open aortic surgery in 9% (15/169) of respondents. Clopidogrel was not discontinued according to time specifications in 8%; ticagrelor in 75%; rivaroxaban in 23%; and dabigatran in 29%, compared to the recommendations of the industrial information sheets. The perioperative antithrombotic therapy in German vascular surgery clinics is not uniform and does not correspond to the current specialist recommendations in a notable proportion of clinics."

Journal • Cardiovascular

The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study. (PubMed, Front Neurol) - "For patients with symptomatic vertebrobasilar artery stenosis, the ticagrelor plus aspirin regimen may provide an alternative therapeutic option to the aspirin plus clopidogrel bisulfate regimen. Furthermore, this regimen may represent a favored treatment choice for specific patient subpopulations."

Journal • Retrospective data • Cardiovascular • CNS Disorders • CYP2C19

Efficacy and safety of ticagrelor versus clopidogrel in acute myocardial infarction-associated cardiogenic shock: a propensity score-matched analysis (HEART FAILURE 2025) - No abstract available

Clinical • Cardiovascular • Myocardial Infarction

Pharmacogenomic Testing for CYP2C19 Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory? (PubMed, J Appl Lab Med) - "Pharmacogenomic testing for CYP2C19 variants is more economically justified for laboratories that serve a population enriched with CYP2C19 LOF alleles, than populations exhibiting a lower allele frequency. Within a clinical laboratory offering testing, restricting testing to certain populations is not ethical."

Biomarker • Journal • Acute Coronary Syndrome • Cardiovascular • Ischemic stroke • CYP2C19

Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention. (PubMed, Am Heart J) - "The TADCLOT trial will provide crucial insights into the comparative efficacy of ticagrelor versus twice-daily clopidogrel in reducing early stent thrombosis and improving outcomes in STEMI patients undergoing primary PCI. The trial will particularly contribute valuable insights for post-PCI care, considering both the economic and genetic context of the high risk South Asian population."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Minimizing STOPP and Beers Criteria Risks in PIM Treatments Using PM-TOM and ChatGPT: A Case Study. (PubMed, Stud Health Technol Inform) - "She was initially prescribed acetaminophen, alendronate, omeprazole, lisinopril, metoprolol, aspirin, citalopram, and vitamin D, which were assessed as inadequate...In the optimized treatment, omeprazole (PPI) was replaced with famotidine (H2-blocker), citalopram (SSRI) with agomelatine (atypical antidepressant), zoledronic acid (bisphosphonate) with denosumab (RANK ligand inhibitor), aspirin (NSAID) with ticagrelor (antiplatelet), and lisinopril with benazepril (ACE inhibitor)...Finally, ChatGPT validated the proposed adjustments, confirming their alignment with the guidelines and highlighting the potential for longer-term benefits. This case study illustrates how a combined use of PM-TOM and AI tools can effectively support the clinical decision-making process by optimizing polypharmacy treatments and minimizing their PIMs, major contributors to morbidity in older adults and high healthcare costs."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Gastroesophageal Reflux Disease • Heart Failure • Hypertension • Immunology • Osteoarthritis • Osteoporosis • Pain • Psychiatry • Rheumatology

Mechanistic insights into the potentiation and toxicity mitigation of myocardial infarction treatment with salvianolate and ticagrelor. (PubMed, Phytomedicine) - "The TG-SAL combination exhibited ideal synergistic effects in enhancing anti-MI activity and reducing TG-induced hyperuricemia, with the medium-dose combination demonstrating the best results. Mechanistically, the medium-dose combination exerted anti-hyperuricemic effects by positively regulating selenium compound metabolic pathways and anti-MI activity by inhibiting cardiac muscle contraction pathways. These findings provide a reference for the rational use of TG and SAL in clinical settings."

Journal • Cardiovascular • Myocardial Infarction • ABCG2

Ticagrelor or dipyridamole plus aspirin may be a promising antiplatelet therapy in patients with minor stroke or transient ischemic attack: a bayesian network meta-analysis. (PubMed, Front Pharmacol) - "Ticagrelor + Aspirin was significantly more effective than Clopidogrel + Aspirin in preventing post-stroke neurological dysfunctions (mRS 0-1), recurrent stroke and major vascular events for up to 90 days. Due to limited studies, the superiority of Dipyridamole + Aspirin is still difficult to conclude, and further high-quality studies are needed to verify the benefits of Dipyridamole + Aspirin in minor stroke or TIAs. https://www.crd.york.ac.uk/prospero/, identifier CRD42024537462."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • CYP2C19